On Wednesday, Intuit Inc. (NASDAQ:INTU)’s shares declined -1.25% to $86.64.
Intuit Inc. (INTU) will host its annual Investor Day on Thursday, Sept. 17 from 8 to 11:30 a.m. Pacific time at its Mountain View, Calif. headquarters.
Chief Executive Officer Brad Smith and Chief Financial Officer Neil Williams will be joined by business leaders to talk about Intuit’s strategy for fiscal year 2016. The company’s fiscal year runs from Aug. 1 to July 31.
Intuit Inc. provides business and financial administration solutions for small businesses, consumers, and accounting professionals primarily in the United States, Canada, the United Kingdom, Australia, India, and Singapore. The company’s Small Business segment provides QuickBooks financial and business administration online services and desktop software; QuickBooks technical support services; financial supplies; and QuickBooks Accountant, QuickBooks Accountant Plus, and QuickBooks Online Accountant, in addition to the QuickBooks ProAdvisor Program for the accounting professionals.
Carnival Corp (NYSE:CCL)’s shares dropped -0.30% to $50.53.
Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) declared a quarterly cash dividend of $0.30 (U.S.) per share. The dividend is payable on September 11, 2015, to shareholders of record on August 21, 2015.
Holders of Carnival Corporation common stock or Carnival plc ADSs will receive a dividend payable in U.S. dollars. The dividend for Carnival plc ordinary shares will be payable in sterling unless shareholders elected to receive the dividend in U.S. dollars by August 21, 2015.
Dividends payable in sterling will be converted from U.S. dollars at the exchange rate quoted by the Bank of England in London at 12 noon on September 1, 2015 (US$1 = 65.13385 pence). Accordingly, the dividend payable in sterling on September 11, 2015, will be 19.54016 pence per share.
Carnival Corporation & plc is the largest cruise company in the world, with a portfolio of 10 cruise brands in North America, Europe, Australia and Asia, comprised of Carnival Cruise Line, Holland America Line, Princess Cruises, Seabourn, AIDA Cruises, Costa Cruises, Cunard, P&O Cruises (Australia), P&O Cruises (UK) and Fathom.
Carnival Corporation operates as a cruise company worldwide. It provides vacations to various cruise destinations. The company offers cruise services under the Carnival Cruise Lines, Holland America Line, Princess Cruises, and Seabourn brand names in North America; and AIDA Cruises, Costa Cruises, Cunard, and P&O Cruises names in Europe, Australia, and Asia.
At the end of Wednesday’s trade, Enterprise Products Partners L.P. (NYSE:EPD)‘s shares dipped -1.28% to $27.06.
Enterprise Products Partners L.P. (EPD) declared that Jim Teague, chief operating officer of Enterprise’s general partner, is planned to present at the Barclays CEO Energy-Power Conference, Tuesday, September 8, 2015 at 12:25 p.m. ET in New York City.
A copy of the slides used for the event will be accessible by 8:00 a.m. ET, Tuesday, September 8, 2015 and may be obtained from the Enterprise website at www.enterpriseproducts.com under the Investors tab.
Enterprise Products Partners L.P. provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals, and refined products in the United States and internationally. Its NGL Pipelines & Services segment provides natural gas processing and related NGL marketing services, in addition to import and export terminal services.
Amgen, Inc. (NASDAQ:AMGN), ended its Wednesday’s trading session with -2.25% loss, and closed at $151.08.
Amgen (AMGN) declared the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.
Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone and is in clinical development for the treatment of SHPT in patients with CKD on hemodialysis. Etelcalcetide is administered intravenously three times per week at the end of each dialysis session. It acts by binding to and activating the calcium-sensing receptor on the parathyroid gland, thereby causing decreases in parathyroid hormone (PTH). Sustained elevations in PTH are known to be associated with noteworthy clinical consequences for patients with CKD.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The companys principal products comprise Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
